(6Z,11Z)-octadeca-6,11-dienoic acid | 50381-82-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (6Z,11Z)-octadeca-6,11-dienoic acid
• 英文别名: 6Z,11Z-octadecadienoic acid
• CAS: 50381-82-3
• 化学式: C₁₈H₃₂O₂
• 分子量: 280.451
• InChiKey: RTJZUCGIUVBZCN-QOTUMQCOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  20
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• IONIZABLE CATIONIC LIPIDS
  申请人：Akagera Medicines, Inc.

  公开号：US20220162521A1

  公开（公告）日：2022-05-26

  The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.

  本公开提供了可用作离子化阳离子脂质体的化合物。这些离子化阳离子脂质体可用于制备脂质纳米粒子，以将治疗性核酸传递到细胞中。改进了阳离子离子化脂质体的稳定性，以防止在储存过程中发生氧化降解。
• Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof
  申请人：Akagera Medicines, Inc.

  公开号：US20220411394A1

  公开（公告）日：2022-12-29

  The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.
• [EN] LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS, AND RELATED METHODS OF USE<br/>[FR] NANOPARTICULES LIPIDIQUES UTILISÉES POUR L'ADMINISTRATION D'ACIDES NUCLÉIQUES, ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：[en]AKAGERA MEDICINES, INC.

  公开号：WO2022115645A1

  公开（公告）日：2022-06-02

  The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with themin vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.